Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phio Pharmaceuticals Corp. filings document material events for a clinical-stage siRNA biopharmaceutical company developing INTASYL® gene-silencing therapeutics in immuno-oncology. Recent 8-K disclosures report quarterly and year-end financial results, PH-762 clinical and safety updates, tumor-response data, and development activities for skin cancer indications including cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
The company's regulatory record also covers material agreements and capital-structure matters, including a cGMP drug-product manufacturing services agreement for PH-762 clinical supply and an at-the-market common-stock offering under a shelf registration statement. Governance disclosures include executive employment-agreement amendments and related compensatory arrangements.
CVI Investments, Inc. and Heights Capital Management, Inc. have reported beneficial ownership tied to Phio Pharmaceuticals Corp. common stock. They report 1,194,719 shares beneficially owned, representing 9.9% of Phio’s common stock. This amount consists entirely of shares issuable upon exercise of warrants, rather than currently outstanding shares.
The warrants are subject to a 9.99% beneficial ownership limitation, meaning they cannot be exercised if doing so would push the reporting persons and their affiliates above that threshold. Heights Capital Management, Inc., as investment manager to CVI Investments, Inc., may be deemed to share voting and dispositive power, but both parties disclaim beneficial ownership beyond their pecuniary interest. Phio’s quarterly report indicated 10,764,428 shares outstanding as of November 11, 2025.
Phio Pharmaceuticals Corp. received an updated ownership report from Intracoastal Capital LLC and its principals Mitchell P. Kopin and Daniel B. Asher. As of December 31, 2025, they may be deemed to beneficially own 1,142,556 shares of common stock through a warrant held by Intracoastal.
The filing states this represents approximately 9.1% of Phio’s common stock, calculated using 11,447,952 shares outstanding as of December 4, 2025 plus the warrant shares. Additional warrants for 149,298 and 759,298 shares are subject to 4.99% beneficial ownership blocker provisions and are excluded from this percentage.
Without these blocker provisions, the reporting persons may be deemed to beneficially own 2,051,152 shares. They certify the securities were not acquired to change or influence control of Phio Pharmaceuticals, and that the information is true, complete, and correct.
Phio Pharmaceuticals reported encouraging early results from its Phase 1b skin cancer trial of PH-762, its INTASYL gene-silencing compound. The Safety Monitoring Committee completed its planned review and found no dose-limiting toxicities or serious adverse events in 22 patients treated across five escalating dose cohorts.
In cutaneous squamous cell carcinoma, the company reports a 65% overall pathological response rate, with 13 of 20 patients responding, including 9 complete responses with 100% tumor clearance. At the highest dose cohort, 6 of 7 patients showed pathological response and 4 had complete responses.
Phio plans an FDA submission in the second quarter of 2026 to seek guidance on next-step trial design for PH-762. Manufacturing and CMC work is progressing, with API expected for a non-human primate study in March 2026 and cGMP material targeted for the second half of 2026.
Phio Pharmaceuticals director Curtis Lockshin received an equity award in the form of restricted stock units. On February 5, 2026, he was granted 16,600 shares of common stock at a price of $0 per share, reflecting a stock-based compensation grant rather than a purchase.
The filing states these shares represent a restricted stock unit award that will vest on the first anniversary of the grant. Following this grant, Lockshin beneficially owns 35,155 shares of Phio Pharmaceuticals common stock in direct ownership, including shares underlying unvested restricted stock units that have been adjusted for prior reverse stock splits.
Phio Pharmaceuticals director Jonathan E. Freeman received a new equity grant. On 02/05/2026, he was awarded 16,600 shares of common stock at a price of $0, in the form of restricted stock units that will vest on the first anniversary of the grant.
After this award, Freeman beneficially owns 32,655 shares, which include shares underlying unvested restricted stock units. The reported share amounts have been adjusted to account for prior reverse stock splits.
Phio Pharmaceuticals director David H. Deming reported an equity award of 23,800 shares of common stock underlying restricted stock units on February 5, 2026. The filing shows the award was recorded at a price of $0 per share and coded as an acquisition.
These restricted stock units will vest on the first anniversary of the grant, and the total beneficial ownership after this transaction is 37,800 shares held directly, including shares underlying unvested restricted stock units.
Phio Pharmaceuticals reported an equity award to its Chief Financial Officer, Lisa Carson. On 02/05/2026, she received 47,000 shares of common stock for $0, representing a restricted stock unit grant that will vest on the first anniversary of the grant. Following this award, she beneficially owns 94,000 shares of Phio common stock, including shares underlying unvested restricted stock units.
Phio Pharmaceuticals director Patricia A. Bradford received 18,500 shares of common stock underlying a restricted stock unit award on February 5, 2026. These shares will vest on the first anniversary of the grant. After this award, she beneficially owns 45,651 common shares directly, including unvested restricted stock units, with amounts adjusted for prior reverse stock splits.
Phio Pharmaceuticals’ Chairman, President and CEO Robert J. Bitterman received 120,000 shares of common stock on February 5, 2026 through a restricted stock unit (RSU) grant. The Form 4 shows the shares were acquired at a price of $0 per share, reflecting an equity award rather than an open‑market purchase.
The 120,000 shares represent RSUs that will vest on the first anniversary of the grant. After this award, Bitterman beneficially owns 411,421 shares of Phio common stock in direct ownership, which includes shares underlying unvested RSUs.
PHIO Pharmaceuticals Corp. reported new clinical results from its intratumoral PH-762 dose-escalation trial in cutaneous carcinoma. The company highlighted that safety and tolerability were favorable across all dose levels. Pathology data showed a 70% overall response rate for squamous cell carcinomas, and among the 14 responders, 10 achieved 100% clearance of their tumors. These findings suggest PH-762 demonstrated meaningful anti-tumor activity in this early study while maintaining a manageable safety profile.